Glaukos (GKOS) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Glaukos GKOS is currently developing the following drugs: Glk-321 Low Dose Bid, Glk-321 Mid Dose Bid, Glk-321 High Dose Bid, Glk-321 High Dose Qd, Sham Procedure, Gen 2 Travoprost Intracameral Implant, Timolol Eye Drops 0.5%, Idose Tr 75 Μg In Conjunction With Cataract Surgery, Sham Procedure In Conjunction With Cataract Surgery, Travoprost Intraocular Implant, Sham Procedure 1, Istent Infinite, Sham Procedure 2, Vehicle, Lufepirsen High Dose, Lufepirsen Low Dose, Vehicle, Nexagon High Dose Concentration, Nexagon Low Dose Concentration, Open-Label Nexagon, G2-Tr Intraocular Implant Containing Travoprost, Sham Surgery + Active-Comparator Eye Drops. These drug candidates are in various stages of clinical development as the company works toward FDA approval.